Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P40692: Variant p.Asp485His

DNA mismatch repair protein Mlh1
Gene: MLH1
Feedback?
Variant information Variant position: help 485 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Aspartate (D) to Histidine (H) at position 485 (D485H, p.Asp485His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In LYNCH2; uncertain significance. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 485 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 756 The length of the canonical sequence.
Location on the sequence: help TSSNPRKRHREDSDVEMVED D SRKEMTAACTPRRRIINLTS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         TSS--NPRKRHREDSDVEMVEDDSRK-EMTAACTPRR----RI-INLTS

Mouse                         TSSPGSSRKRHREDSDVEMVENASGK-EMTAACYPRR----

Rat                           PSSPGSSRKRHPEDSDVEMMENDSRK-EMTAACYPRR----

Slime mold                    TTTTTTTTTTATTKSNSPASKNDIKKLQEHTFITPRKTRKY

Baker's yeast                 YKVPSIADD---EKNALPISKDGYIR-------VPKE----

Fission yeast                 ANSNKNATNDIKDLQTEEIVEEGNS----------------

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 756 DNA mismatch repair protein Mlh1
Region 400 – 491 Disordered
Region 410 – 650 Interaction with EXO1
Compositional bias 464 – 491 Basic and acidic residues
Modified residue 477 – 477 Phosphoserine
Mutagenesis 471 – 471 K -> N. Affects binding to importins alpha, including KPNA2, hence may affect import to the nucleus.
Mutagenesis 472 – 472 R -> N. Affects binding to importins alpha, including KPNA2, hence may affect import to the nucleus.



Literature citations
hMLH1 and hMSH2 mutations in families with familial clustering of gastric cancer and hereditary non-polyposis colorectal cancer.
Kim J.C.; Kim H.C.; Roh S.A.; Koo K.H.; Lee D.H.; Yu C.S.; Lee J.H.; Kim T.W.; Lee H.I.; Beck N.E.; Bodmer W.F.;
Cancer Detect. Prev. 25:503-510(2001)
Cited for: VARIANTS GASTRIC CANCER ARG-106; GLN-109 AND LYS-635; VARIANTS LYNCH2 GLY-234; ILE-321; HIS-485 AND ALA-631; VARIANT CRC ILE-472;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.